Arrival of direct antiviral agent therapy for hepatitis C sparks debate of who to treat first
Wednesday, May 25, 2011 - 10:30
in Health & Medicine
For many patients with the hepatitis C virus (HCV), direct antiviral agents (DAA) offer a potential cure for the disease. The Food and Drug Administration (FDA) has recently approved two new DAAs, telaprevir and boceprevir, and with that clinicians must now decide who should be the first to receive this treatment. Discussion of this timely topic is covered in a new article.